UK DOCTORS CHANGE TACK ON GENERICS

10 July 1994

Local Medical Committees' representatives, at their annual conference, overturned a decision taken in March by the UK General Medical Services Committee to permit generic substitution by pharmacists unless the prescribing doctor had specifically instructed that this should not be done.

Cheshire LMC representative Peter Maddon told the conference that "this mysterious decision by the GMSC has been made without explanation and without a mandate from conference." How humiliating, he added, that a week after the GMSC's decision, the Health Secretary, Virginia Bottomley, told pharmaceutical companies that she remained to be convinced on generic substitution (Marketletter April 25).

Representing Suffolk LMC, Michael Freestone told the conference that "erratic behavior" has been seen from generics, and warned that generics can be dangerous to patients and could lead to legal problems for doctors or pharmacists, who could be sued if something went wrong.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight